People
Filter News
Found 62,496 articles
-
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
3/29/2024
Adlai Nortye Ltd. announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.
-
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
3/28/2024
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the appointment of Colleen Sjogren as Chief Commercial Officer.
-
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
3/28/2024
TransCode Therapeutics, Inc. announced that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.
-
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
3/28/2024
Third Harmonic Bio, Inc. announced the appointment of Geoff McDonough, M.D., to its Board of Directors.
-
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
3/28/2024
Zymeworks Inc. announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024.
-
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
3/28/2024
MAIA Biotechnology, Inc. announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual purchases of 69,282 and 6,928 shares of common stock, respectively, as part of the Company’s recent private placement of common stock and warrants.
-
Inventiva announces the nomination of Andre Turenne as Director
3/28/2024
Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced the nomination of Andre Turenne to its Board of Directors.
-
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
3/28/2024
Zura Bio Limited a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, reported full year 2023 financial results and recent business highlights.
-
Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer
3/28/2024
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).
-
Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors
3/28/2024
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.
-
See our latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
-
KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors
3/27/2024
KeifeRx announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.
-
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
3/27/2024
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that it has entered into a Restructuring Support Agreement with certain funds managed by Highbridge Capital Management, LLC, the Company’s principal lender.
-
Xcell Biosciences Announces New Scientific and Business Advisory Board
3/27/2024
Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.
-
Stephanie Burke Named as VGXI's New Chief Accounting Officer
3/27/2024
VGXI, Inc., a leading contract developer and manufacturer specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, is pleased to announce the appointment of Stephanie Burke as the Chief Accounting Officer for VGXI.
-
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
3/27/2024
Dyne Therapeutics, Inc. announced that it has granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox.
-
One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors
3/27/2024
One Biosciences, a Home Biosciences biotech company, leveraging the power of single-cell analysis and A.I. to identify a new generation of precision medicine targets and develop new treatments, announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.
-
XORTX Announces New Clinical Advisory Board Member - March 27, 2024
3/27/2024
XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease, is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
-
IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer
3/27/2024
IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.
-
Castle Biosciences Announces Updates to its Board of Directors
3/27/2024
Castle Biosciences, Inc. announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle’s 2024 Annual Meeting of Stockholders, expected to be held in May 2024.